Breast cancer treatment with fewer potential side effects has equally good patient outcomes Women diagnosed with breast cancer and treated with a one-week regimen of partial breast radiation after the surgical removal of the tumor, or lumpectomy, saw no increase in cancer recurrence or difference in cosmetic outcomes compared to women who received radiation of the entire breast for a period of up to six weeks after surgery.
Researchers define unique group of high-risk lymphoma patients About 20 percent of follicular lymphoma patients consistently experience their disease coming back within two years of being treated with the latest therapies. New research confirms that patients in this group have very poor survival outcomes; 50 percent die in five years. People who relapse early may have a disease with distinctly different biology and should not be approached the same at diagnosis nor at the time of relapse in terms of therapies
Blood test for lung cancer a step closer Two oncologists and a research scientist are helping pave the way to an easier, more accurate, less invasive way to screen for the most common form of lung cancer. Lung cancer the number one cancer killer in the United States
Treatment with PI3K inhibitors may cause cancers to become more aggressive and metastatic The enzyme PI3K appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target. However, PI3K inhibitors have only shown modest clinical activity. Now, new research shows that treatment with PI3K inhibitors alone may actually make a patient’s cancer even worse by promoting more aggressive tumor cell behavior and increasing the cancer’s potential of spreading to other organs.